dc.creatorPérez Lloret, Santiago
dc.creatorPeralta, María Cecilia
dc.creatorBarrantes, Francisco José
dc.date2022-06-29T12:16:36Z
dc.date2022-06-29T12:16:36Z
dc.date2016
dc.identifierPérez Lloret, S., Peralta, M.C., Barrantes, F.J. Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration [en línea]. Expert Opinion on Pharmacotherapy. 2016, 17(18) doi:10.1080/14656566.2016.1254189 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/14304
dc.identifier1465-6566
dc.identifier1744-7666 (online)
dc.identifierhttps://repositorio.uca.edu.ar/handle/123456789/14304
dc.identifier10.1080/14656566.2016.1254189
dc.identifier27785919
dc.descriptionAbstract: Dopamine depletion is one of the most important features of Parkinson's Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter systems in the pathophysiology of PD. Cholinergic degeneration contributes to gait impairments, cognitive impairment, psychosis, and REM-sleep disturbances, among other symptoms. Areas covered: In this review, we explore the idea that enhancing cholinergic tone by pharmacological or neurosurgical procedures could be a first-line therapeutic strategy for the treatment of symptoms derived from cholinergic degeneration in PD. Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation. Interesting results suggest the efficacy of these drugs in the treatment of gait dysfunction. Evidence on the clinical effects of these drugs for psychosis and REM-sleep disturbances is still weak. Stimulation of the pedunculo-pontine tegmental nuclei (which provide cholinergic innervation to the brain stem and subcortical nuclei) has also been used with some success for the treatment of gait dysfunction. Anticholinergic drugs should be used with caution in PD, as they may aggravate cholinergic symptoms. Notwithstanding, in some patients they might help control parkinsonian motor symptoms.
dc.formatapplication/pdf
dc.languageeng
dc.publisherTaylor & Francis
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.sourceExpert Opinion on Pharmacotherapy. 2016, 17(18)
dc.subjectTRATAMIENTO MEDICO
dc.subjectENFERMEDAD DE PARKINSON
dc.subjectNEURODEGENERACION
dc.subjectDETERIORO COGNITIVO
dc.subjectDEMENCIA
dc.titlePharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
dc.typeArtículo


Este ítem pertenece a la siguiente institución